Citations (115)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Anup Kumar Singh, Ayushi Verma, Akhilesh Singh, Rakesh Kumar Arya, Shrankhla Maheshwari, Priyank Chaturvedi, Mushtaq Ahmad Nengroo, Krishan Kumar Saini, Achchhe Lal Vishwakarma, Kavita Singh, Jayanta Sarkar & Dipak Datta. (2021) Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells. Epigenetics 16:2, pages 144-161.
Read now
Read now
Ali Sak, Dennis Kübler, Kristina Bannik, Michael Groneberg, Sonja Strunz, Ralf Kriehuber & Martin Stuschke. (2017) Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines. International Journal of Radiation Biology 93:5, pages 494-506.
Read now
Read now
Jane Borley & Robert Brown. (2015) Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. Annals of Medicine 47:5, pages 359-369.
Read now
Read now
Angiolo Gadducci, Claudia Sergiampietri, Nora Lanfredini & Ilaria Guiggi. (2014) Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecological Endocrinology 30:4, pages 266-271.
Read now
Read now
Tao Li, Jing Cai, Hui Ding, Linjuan Xu, Qiang Yang & Zehua Wang. (2014) EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Cancer Biology & Therapy 15:3, pages 271-278.
Read now
Read now
Stuart Campbell, Ismail Hassan Ismail, Leah C Young, Guy G Poirier & Michael J Hendzel. (2013) Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle 12:16, pages 2675-2683.
Read now
Read now
Ali R Ozes & Kenneth P Nephew. (2013) 3D culture adds an extra dimension to targeted epigenetic therapies. Cell Cycle 12:14, pages 2173-2174.
Read now
Read now
Yiping Huang, Dafna Kesselman, Darya Kizub, Rafael Guerrero-Preston & Edward A. Ratovitski. (2013) Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure. Cell Cycle 12:4, pages 684-697.
Read now
Read now
Articles from other publishers (107)
Shadia Hamoud Alshahrani, Triani Yuliastanti, F. Al-dolaimy, Nadezhda L. Korotkova, Irodakhon Rasulova, Abbas F. Almulla, Ali Alsaalamy, Saad Hayif Jasim Ali, Mohammed Qasim Alasheqi & Yasser Fakri Mustafa. (2023) A glimpse into let-7e roles in human disorders; friend or foe?. Pathology - Research and Practice, pages 154992.
Crossref
Crossref
Minxian Li, Mei Jiang, Mengting Chen, Lilusi Ma, Xiaocui Fang, Yanlian Yang & Chen Wang. (2023) Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide. Nano Research 16:11, pages 12864-12879.
Crossref
Crossref
Shao-hai Wang, Lin Liu, Ke-yong Bao, Yi-fan Zhang, Wen-wen Wang, Shi Du, Na-er Jia, Suo Suo, Jing Cai, Jian-feng Guo & Gang Lv. (2023) EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A. Current Medical Science 43:4, pages 794-802.
Crossref
Crossref
Ying Cao. (2023) Neural induction drives body axis formation during embryogenesis, but a neural induction-like process drives tumorigenesis in postnatal animals. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Mona Safari Sharafshadeh, Farzaneh Tafvizi, Parvin Khodarahmi & Somayeh Ehtesham. (2023) Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy. International Journal of Biological Macromolecules 235, pages 123686.
Crossref
Crossref
Dino Bekric, Daniel Neureiter, Celina Ablinger, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Martin Jakab, Johannes Bischof, Ulrich Koller, Tobias Kiesslich & Christian Mayr. (2023) Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer. Cancers 15:5, pages 1569.
Crossref
Crossref
Anne Uebel, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkötter & Dennis Gerloff. (2023) Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences 24:3, pages 1963.
Crossref
Crossref
Anne-Marie Baird & Steven G. Gray. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
577
611
.
Xifeng Xiong, Xudong Lai, Jinli Zhang, Qingqi Meng, Pengzhen Wang, Shengnan Qin, Wei Liu, Yongxuan Wang, Zhuo Yao, Di Wang, Xiaojian Li, Zhihe Liu & Haixiong Miao. (2022) FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3. Bioscience Reports 42:9.
Crossref
Crossref
Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić & Koraljka Gall Trošelj. (2022) EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies. Cancers 14:19, pages 4761.
Crossref
Crossref
Chen Lyu, Lili Wang, Birgit Stadlbauer, Elfriede Noessner, Alexander Buchner & Heike Pohla. (2022) Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG). Cancers 14:17, pages 4200.
Crossref
Crossref
Na Li, Feng Geng, Shu-Mei Liang & Xiaoyan Qin. (2022) USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer. Cellular Signalling 96, pages 110351.
Crossref
Crossref
Lin Zhao, Hongjie Guo, Xi Chen, Wenxin Zhang, Qiaojun He, Ling Ding & Bo Yang. (2022) Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. European Journal of Pharmacology 927, pages 175071.
Crossref
Crossref
Cheol-Hee Shin, Su Chan Park, Il-Geun Park, Hyerim Kim, Byoungha An, Choongil Lee, Sang-Heon Kim, Juyong Lee, Ji Min Lee & Seung Ja Oh. (2022) Cytosolic microRNA-inducible nuclear translocation of Cas9 protein for disease-specific genome modification. Nucleic Acids Research 50:10, pages 5919-5933.
Crossref
Crossref
Mei Jiang, Xiaocui Fang, Lilusi Ma, Mingpeng Liu, Mengting Chen, Jingyi Liu, Yanlian Yang & Chen Wang. (2022) A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer. International Journal of Pharmaceutics 622, pages 121894.
Crossref
Crossref
Victoria Parreno, Anne-Marie Martinez & Giacomo Cavalli. (2022) Mechanisms of Polycomb group protein function in cancer. Cell Research 32:3, pages 231-253.
Crossref
Crossref
Cheang Wei Chan, Chin Yoong Yong, How Mun Chang, Pei Ying Ng, Fabian Davamani, Ebenezer Chitra, Vannajan Sanghiran Lee, Kong Wai Tan, Mohd Jamil Maah & Chew Hee Ng. (2022) Anticancer chiral and racemic ternary copper(II) complexes: Multiple mechanisms and epigenetic histone methyltransferase enzymes as novel targets. Polyhedron 213, pages 115617.
Crossref
Crossref
Fuwen Yao, Yongqiang Zhan, Changzheng Li, Ying Lu, Jiao Chen, Jing Deng, Zijing Wu, Qi Li, Yi’an Song, Binhua Chen, Jinjun Chen, Kuifeng Tian, Zuhui Pu, Yong Ni & Lisha Mou. (2022) Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Marina Baretti & Nilofer S. Azad. 2022. Epigenetics and DNA Damage. Epigenetics and DNA Damage
227
252
.
Madhura Ketkar & Shilpee Dutt. 2022. Metabolism and Epigenetic Regulation: Implications in Cancer. Metabolism and Epigenetic Regulation: Implications in Cancer
473
502
.
Brett M. Reid, Shraddha Vyas, Zhihua Chen, Ann Chen, Peter A. Kanetsky, Jennifer B. Permuth, Thomas A. Sellers & Ozlen Saglam. (2021) Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma. BMC Cancer 21:1.
Crossref
Crossref
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, Seema Singh, Annelise Wilhite, Santanu Dasgupta, Rodney Paul Rocconi & Ajay Pratap Singh. (2021) Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Seminars in Cancer Biology 77, pages 99-109.
Crossref
Crossref
Yusuke Aoki, Yasunori Tome, Qinghong Han, Jun Yamamoto, Kazuyuki Hamada, Noriyuki Masaki, Michael Bouvet, Kotaro Nishida & Robert M. Hoffman. (2021) Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation. Biochemistry and Biophysics Reports 28, pages 101177.
Crossref
Crossref
Iga K. Mieczkowska, Garyfallia Pantelaiou-Prokaki, Evangelos Prokakis, Geske E. Schmidt, Lukas C. Müller-Kirschbaum, Marcel Werner, Madhobi Sen, Taras Velychko, Katharina Jannasch, Christian Dullin, Joanna Napp, Klaus Pantel, Harriet Wikman, Maria Wiese, Christof M. Kramm, Frauke Alves & Florian Wegwitz. (2021) Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. Cell Death & Disease 12:12.
Crossref
Crossref
Xuan Zhang, Qing Li, Aibei Du, Yifei Li, Qing Shi, Yanrong Chen, Yang Zhao, Bin Wang & Feng Pan. (2021) Adipocytic Glutamine Synthetase Upregulation via Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Farshad Nassiri, Justin Z Wang, Olivia Singh, Shirin Karimi, Tatyana Dalcourt, Nazanin Ijad, Neda Pirouzmand, Ho-Keung Ng, Andrea Saladino, Bianca Pollo, Francesco Dimeco, Stephen Yip, Andrew Gao, Kenneth D Aldape, Gelareh Zadeh, Kenneth Aldape, Karolyn Au, Jill Barnholtz-Sloan, Felix Behling, Wenya (Linda) Bi, Priscilla Brastianos, Nicholas Butowski, Chaya Brodie, Aaron Cohen-Gadol, Marta Couce, Francesco Dimeco, Kate Drummond, Ian Dunn, Aaron Cohen-Gadol, Eva Galanis, Norbert Galldiks, Caterina Giannini, Roland Goldbrunner, Oliver Hanemann, Christel Herold-Mende, Craig Horbinski, Raymond Huang, Mohsen Javadpour, Michael Jenkinson, Christine Jungk, Timothy Kaufmann, Boris Krischek, Sylvia Kurz, Daniel Lachance, Christian Lafougere, Katrin Lamszus, Ian Lee, Tathiana Malta, Serge Makarenko, Christian Mawrin, Michael McDermott, Christopher Millward, Jennifer Moliterno-Gunel, Andrew Morokoff, Farshad Nassiri, H K Ng, Houtan Noushmehr, Arie Perry, Laila Poisson, Bianco Pollo, Aditya Ragunathan, David Raleigh, Mirjam Renovanz, Franz Ricklefs, Felix Sahm, Andrea Saladino, Antonio Santacroce, Thomas Santarius, Christian Schichor, Nils Schimdt, Jens Schittenhelm, Warren Selman, Helen Shih, Jim Snyder, Matja Snuderl, Andrew Sloan, Suganth Suppiah, Erik Sulman, Ghazaleh Tabatabai, Marcos Tatagiba, Marcos Timmer, Joerg-Christian Tonn, Andreas Von Deimling, Michael Vogelbaum, Tobias Walbert, Justin Wang, Patrick Wen, Manfred Westphal, Stephen Yip & Gelareh Zadeh. (2021) Loss of H3K27me3 in meningiomas. Neuro-Oncology 23:8, pages 1282-1291.
Crossref
Crossref
Sven Rottenberg, Carmen Disler & Paola Perego. (2020) The rediscovery of platinum-based cancer therapy. Nature Reviews Cancer 21:1, pages 37-50.
Crossref
Crossref
Cheng Yang, Jiayu Zhang, Yukui Ma, Chunfu Wu, Wei Cui & Lihui Wang. (2020) Histone methyltransferase and drug resistance in cancers. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Dongbo Wu, Fanglan Wu, Birong Li, Wei Huang & Donglian Wang. (2020) EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer. Cancer Cell International 20:1.
Crossref
Crossref
Babita Kaundal, Avinash Chandra Kushwaha, Anup Kumar Srivastava, Surajit Karmakar & Subhasree Roy Choudhury. (2020) A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy. Journal of Materials Chemistry B 8:37, pages 8658-8670.
Crossref
Crossref
Jinghui Jia, Xiaoxin Yang, Qing Zhao, Feiquan Ying, E Cai, Si Sun & Xiaoqi He. (2020) BNIP3 contributes to cisplatin‐induced apoptosis in ovarian cancer cells. FEBS Open Bio 10:8, pages 1463-1473.
Crossref
Crossref
Ali A. Alshamrani. (2020) Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?. Frontiers in Oncology 10.
Crossref
Crossref
Allyson E. Koyen, Matthew Z. Madden, Dongkyoo Park, Elizabeth V. Minten, Priya Kapoor-Vazirani, Erica Werner, Neil T. Pfister, Ramona Haji-Seyed-Javadi, Hui Zhang, Jie Xu, Nikita Deng, Duc M. Duong, Turner J. Pecen, Zoë Frazier, Zachary D. Nagel, Jean-Bernard Lazaro, Kent W. Mouw, Nicholas T. Seyfried, Carlos S. Moreno, Taofeek K. Owonikoko, Xingming Deng & David S. Yu. (2020) EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene 39:25, pages 4798-4813.
Crossref
Crossref
Si Sun, Qiang Yang, E Cai, Bangxing Huang, Feiquan Ying, Yiping Wen, Jing Cai & Ping Yang. (2020) EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer. PeerJ 8, pages e9052.
Crossref
Crossref
Zhong Wan, Huabo Jiang, Li Li, Shuhui Zhu, Jingjing Hou & Yongsheng Yu. (2020) Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers. Bioorganic & Medicinal Chemistry 28:7, pages 115379.
Crossref
Crossref
Francesca Citron & Linda Fabris. (2020) Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin. Cancers 12:3, pages 682.
Crossref
Crossref
Jae Eun Lee, Chan Mi Park & Jung Hwa Kim. (2020) USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells. Genetics and Molecular Biology 43:2.
Crossref
Crossref
Chin-Jui Wu, Vignesh Sundararajan, Bor-Ching Sheu, Ruby Yun-Ju Huang & Lin-Hung Wei. (2019) Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. Cancers 12:1, pages 24.
Crossref
Crossref
Ratnakar Singh, Zeeshan Fazal, Andrea K. Corbet, Emmanuel Bikorimana, Jennifer C. Rodriguez, Ema M. Khan, Khadeeja Shahid, Sarah J. Freemantle & Michael J. Spinella. (2019) Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. Cancers 11:6, pages 796.
Crossref
Crossref
Jing Sun, Xin Cai, Mingo MH Yung, Wei Zhou, Jing Li, Yi Zhang, Zhuqing Li, Stephanie S. Liu, Annie N. Y. Cheung, Hextan Y. S. Ngan, Yiliang Li, Zhijun Dai, Yan Kai, Alexandros Tzatsos, Weiqun Peng, David W. Chan & Wenge Zhu. (2018) miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 38:4, pages 564-580.
Crossref
Crossref
Qilian Yang, Yuqing Yang, Nianxin Zhou, Kexin Tang, Wayne Bond Lau, Bonnie Lau, Wei Wang, Lian Xu, Zhengnan Yang, Shuang Huang, Xin Wang, Tao Yi, Xia Zhao, Yuquan Wei, Hongjing Wang, Linjie Zhao & Shengtao Zhou. (2018) Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer 17:1.
Crossref
Crossref
Shigeki Nakagawa, Hirohisa Okabe, Mayuko Ouchi, Ryuma Tokunaga, Naoki Umezaki, Takaaki Higashi, Takatoshi Kaida, Kota Arima, Yuki Kitano, Hideyuki Kuroki, Kosuke Mima, Hidetoshi Nitta, Katsunori Imai, Daisuke Hashimoto, Yo-ichi Yamashita, Akira Chikamoto & Hideo Baba. (2018) Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. HPB 20:10, pages 939-948.
Crossref
Crossref
Xi Wang, Hui Chen, Yiping Wen, Xiaoxin Yang, Qing Han, Ping Jiang, Zaiju Huang, Jing Cai & Zehua Wang. (2018) Dicer affects cisplatin‑mediated apoptosis in epithelial ovarian cancer cells. Molecular Medicine Reports.
Crossref
Crossref
Si Sun, Simei Zhao, Qiang Yang, Wenwen Wang, E Cai, Yiping Wen, Lili Yu, Zehua Wang & Jing Cai. (2018) Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation. Cancer Science 109:6, pages 1853-1864.
Crossref
Crossref
Ali R. Özeş, Nick Pulliam, Mustafa G. Ertosun, Özlem Yılmaz, Jessica Tang, Ece Çopuroğlu, Daniela Matei, Osman N. Özeş & Kenneth P. Nephew. (2018) Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. Oncogene 37:26, pages 3589-3600.
Crossref
Crossref
Dan Liu, Xiao-Xue Zhang, Meng-Chen Li, Can-Hui Cao, Dong-Yi Wan, Bi-Xin Xi, Jia-Hong Tan, Ji Wang, Zong-Yuan Yang, Xin-Xia Feng, Fei Ye, Gang Chen, Peng Wu, Ling Xi, Hui Wang, Jian-Feng Zhou, Zuo-Hua Feng, Ding Ma & Qing-Lei Gao. (2018) C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nature Communications 9:1.
Crossref
Crossref
Guiju Tang, Jianfeng Guo, Yapei Zhu, Zaiju Huang, Ting Liu, Jing Cai, Lili Yu & Zehua Wang. (2018) Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. International Journal of Oncology.
Crossref
Crossref
Bayley A. Jones, Sooryanarayana Varambally & Rebecca C. Arend. (2018) Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics 17:3, pages 591-602.
Crossref
Crossref
Lisa B. Caruso, Kayla A. Martin, Elisabetta Lauretti, Michael Hulse, Micheal Siciliano, Lena N. Lupey-Green, Aaron Abraham, Tomasz Skorski & Italo Tempera. (2018) Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget 9:12, pages 10585-10605.
Crossref
Crossref
Chang Yu, Binbin Ding, Xinyang Zhang, Xiaoran Deng, Kerong Deng, Ziyong Cheng, Bengang Xing, Dayong Jin, Ping'an Ma & Jun Lin. (2018) Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo. Biomaterials 155, pages 112-123.
Crossref
Crossref
Jill K. Alldredge & Ramez N. Eskander. (2017) EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecologic Oncology Research and Practice 4:1.
Crossref
Crossref
Fahim Ahmad, Shruti Patrick, Touseef Sheikh, Vikas Sharma, Pankaj Pathak, Prit Benny Malgulwar, Anupam Kumar, Shanker Datt Joshi, Chitra Sarkar & Ellora Sen. (2017)
Telomerase reverse transcriptase (TERT) ‐ enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and
DNA
damage responses in glioblastoma
. Journal of Neurochemistry 143:6, pages 671-683.
Crossref
Crossref
Elisa Paolicchi, Lorenzo Fornaro, Stefano Landi, Sushilaben Rigas & Francesco Crea. (2017) EZH2 Single Nucleotide Variants (SNVs): Diagnostic and Prognostic Role in 10 Solid Tumor Types. Epigenomes 1:3, pages 18.
Crossref
Crossref
Jia Wang, Peng Cheng, Marat S. Pavlyukov, Hai Yu, Zhuo Zhang, Sung-Hak Kim, Mutsuko Minata, Ahmed Mohyeldin, Wanfu Xie, Dongquan Chen, Violaine Goidts, Brendan Frett, Wenhao Hu, Hongyu Li, Yong Jae Shin, Yeri Lee, Do-Hyun Nam, Harley I. Kornblum, Maode Wang & Ichiro Nakano. (2017) Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. Journal of Clinical Investigation 127:8, pages 3075-3089.
Crossref
Crossref
Yiping Wen, Jing Cai, Yaya Hou, Zaiju Huang & Zehua Wang. (2017) Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget 8:23, pages 37974-37990.
Crossref
Crossref
A R Özeş, D F Miller, O N Özeş, F Fang, Y Liu, D Matei, T Huang & K P Nephew. (2016) NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene 35:41, pages 5350-5361.
Crossref
Crossref
Ying Zhu, Liqiong Cai, Jing Guo, Na Chen, Xiaoqing Yi, Yong Zhao, Jing Cai & Zehua Wang. (2016) Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression. Tumor Biology 37:10, pages 14009-14023.
Crossref
Crossref
Xu-ming Ji, Zhi-chun Wu, Guo-wei Liu, Hua-yun Yu, Heng Liu, Zheng-tao Wang, Xiao-hui Wei & Bing Ouyang. (2015) Wenxia Changfu Formula (温下肠腑方) induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice. Chinese Journal of Integrative Medicine 22:10, pages 752-758.
Crossref
Crossref
Yang SunLong JinJia-hua LiuYu-xia SuiLi-li HanXiao-li Shen. (2016) Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy. Cancer Biotherapy and Radiopharmaceuticals 31:7, pages 246-252.
Crossref
Crossref
Jiameng Huang, Liang Zhou, Hui Chen, Chunping Wu, Zhang Duo & Yanping Zhang. (2016) EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells. Oncology Letters 12:2, pages 837-846.
Crossref
Crossref
Matthieu Meryet-Figuière, Bernard Lambert, Pascal Gauduchon, Nicolas Vigneron, Emilie Brotin, Laurent Poulain & Christophe Denoyelle. (2016) An overview of long non-coding RNAs in ovarian cancers. Oncotarget 7:28, pages 44719-44734.
Crossref
Crossref
Rebecca A. Jackson & Ee Sin Chen. (2016) Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. Pharmacology & Therapeutics 162, pages 69-85.
Crossref
Crossref
Jin-Feng Lv, Lei Hu, Wei Zhuo, Cong-Min Zhang, Hong-Hao Zhou & Lan Fan. (2015) Epigenetic alternations and cancer chemotherapy response. Cancer Chemotherapy and Pharmacology 77:4, pages 673-684.
Crossref
Crossref
Tzu-Hung Hsiao, Yu-Chiao Chiu, Pei-Yin Hsu, Tzu-Pin Lu, Liang-Chuan Lai, Mong-Hsun Tsai, Tim H.-M. Huang, Eric Y. Chuang & Yidong Chen. (2016) Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers. Scientific Reports 6:1.
Crossref
Crossref
Ang Sun. 2016. Gynecological Cancers. Gynecological Cancers
23
47
.
Madalene A. Earp & Julie M. Cunningham. (2015) DNA methylation changes in epithelial ovarian cancer histotypes. Genomics 106:6, pages 311-321.
Crossref
Crossref
Mónica Martínez-Fernández, Carolina Rubio, Cristina Segovia, Fernando López-Calderón, Marta Dueñas & Jesús Paramio. (2015) EZH2 in Bladder Cancer, a Promising Therapeutic Target. International Journal of Molecular Sciences 16:11, pages 27107-27132.
Crossref
Crossref
Xu Wang, Bo Hu, Hugang Shen, Hao Zhou, Xiaofeng Xue, Yan Chen, Shaoji Chen, Ye Han, Bin Yuan, Hong Zhao, Qiaoming Zhi & Yuting Kuang. (2015) Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis. Biomedicine & Pharmacotherapy 75, pages 218-225.
Crossref
Crossref
Jin Zhu, Dong-Rong Yang, Yin Sun, Xiaofu Qiu, Hong-Chiang Chang, Gonghui Li, Yuxi Shan & Chawnshang Chang. (2015) TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression. Molecular Cancer Therapeutics 14:6, pages 1445-1453.
Crossref
Crossref
Huali Wang, Yunhai Yu, Chen Chen, Qian Wang, Taisheng Huang, Fangzhen Hong & Lin Zhu. (2015) Involvement of enhancer of zeste homolog�2 in cisplatin‑resistance in ovarian cancer cells by interacting with several genes. Molecular Medicine Reports.
Crossref
Crossref
Wen Zhou, Jian Wang, Wang-Ying Man, Qing-Wei Zhang & Wen-Gui Xu. (2015) siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells. Asian Pacific Journal of Cancer Prevention 16:6, pages 2425-2430.
Crossref
Crossref
Yan-Long Liu, Xu Gao, Yang Jiang, Gan Zhang, Zi-Cheng Sun, Bin-Bin Cui & Yan-Mei Yang. (2014) Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Journal of Cancer Research and Clinical Oncology 141:4, pages 661-669.
Crossref
Crossref
Steven G. Gray. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
613
637
.
Lin Liu, Jianfeng Guo, Lili Yu, Jing Cai, Ting Gui, Huijuan Tang, Limian Song, Jia Wang, Fang Han, Chun Yang, Chunyan Chen, Ariel Marks & Zehua Wang. (2014) miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumor Biology 35:12, pages 12619-12626.
Crossref
Crossref
Shou-Hung TangHsu-Shan HuangHong-Ui WuYi-Ta TsaiMei-Jen ChuangCheng-Ping YuShih-Ming HuangGuang-Huan SunSun-Yran ChangPei-Wen HsiaoDah-Shyong YuTai-Lung Cha. (2014)
Pharmacologic down-regulation of EZH2 suppresses bladder cancer
in vitro
and
in vivo
. Oncotarget 5:21, pages 10342-10355.
Crossref
Crossref
Catherine Baugé, Céline Bazille, Nicolas Girard, Eva Lhuissier & Karim Boumediene. (2014) Histone methylases as novel drug targets: developing inhibitors of EZH2. Future Medicinal Chemistry 6:17, pages 1943-1965.
Crossref
Crossref
Chunhua Xu, Keke Hao, Huidi Hu, Zhihong Sheng, Jun Yan, Qingbo Wang & Like Yu. (2014) Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy. Lung Cancer 86:2, pages 268-273.
Crossref
Crossref
Zhibo Hou, Wei Zhao, Ji Zhou, Lan Shen, Ping Zhan, Chunhua Xu, Cunjie Chang, Hui Bi, Jue Zou, Xin Yao, Ruimin Huang, Like Yu & Jun Yan. (2014) A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. The International Journal of Biochemistry & Cell Biology 53, pages 380-388.
Crossref
Crossref
Hirohito Yamaguchi & Mien-Chie Hung. (2014) Regulation and Role of EZH2 in Cancer. Cancer Research and Treatment 46:3, pages 209-222.
Crossref
Crossref
Deborah J. Marsh, Jaynish S. Shah & Alexander J. Cole. (2014) Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets. Frontiers in Oncology 4.
Crossref
Crossref
Gauri Deb, Anup Kumar Singh & Sanjay Gupta. (2014) EZH2: Not EZHY (Easy) to Deal. Molecular Cancer Research 12:5, pages 639-653.
Crossref
Crossref
Mou-Ze Liu, Howard L McLeod, Fa-Zhong He, Xiao-Ping Chen, Hong-Hao Zhou, Yan Shu & Wei Zhang. (2014) Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics 15:5, pages 699-715.
Crossref
Crossref
Lingbo Zhao, Yang Yu, Jie Wu, Jing Bai, Yuzhen Zhao, Chunming Li, Wenjing Sun & Xiumei Wang. (2014) Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene 537:2, pages 197-202.
Crossref
Crossref
Monjri M. Shah & Charles N. Landen. (2014) Ovarian cancer stem cells: Are they real and why are they important?. Gynecologic Oncology 132:2, pages 483-489.
Crossref
Crossref
Robert Brown, Juliane Steinmann, Janet Graham & Ros Glasspool. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
299
317
.
Zhongwu Li, Yanling Wang, Jing Qiu, Qiang Li, Chunping Yuan, Wei Zhang, Dongmiao Wang, Jinhai Ye, Hongbin Jiang, Jianrong Yang & Jie Cheng. (2013) The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget 4:12, pages 2532-2549.
Crossref
Crossref
Carmen Behrens, Luisa M. Solis, Heather Lin, Ping Yuan, Ximing Tang, Humam Kadara, Erick Riquelme, Hector Galindo, Cesar A. Moran, Neda Kalhor, Stephen G. Swisher, George R. Simon, David J. Stewart, J. Jack Lee & Ignacio I. Wistuba. (2013) EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma. Clinical Cancer Research 19:23, pages 6556-6565.
Crossref
Crossref
J. Lopez, S. Banerjee & S.B. Kaye. (2013) New developments in the treatment of ovarian cancer—future perspectives. Annals of Oncology 24, pages x69-x76.
Crossref
Crossref
Chuying Ma, Guangfu Yin, Danhong Yan, Xueling He, Li Zhang, Yan Wei & Zhongbing Huang. (2013)
A novel peptide specifically targeting ovarian cancer identified by
in vivo
phage display
. Journal of Peptide Science 19:12, pages 730-736.
Crossref
Crossref
Zehua Wang. (2013) Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression. International Journal of Molecular Medicine.
Crossref
Crossref
J Cai, C Yang, Q Yang, H Ding, J Jia, J Guo, J Wang & Z Wang. (2013) Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2:10, pages e75-e75.
Crossref
Crossref
Dong Hoon Suh, Mi-Kyung Kim, Hee Seung Kim, Hyun Hoon Chung & Yong Sang Song. (2013) Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer. Journal of Cancer Prevention 18:3, pages 227-234.
Crossref
Crossref
Bradley P. Coe, Kelsie L. Thu, Sarit Aviel-Ronen, Emily A. Vucic, Adi F. Gazdar, Stephen Lam, Ming-Sound Tsao & Wan L. Lam. (2013) Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer. PLoS ONE 8:8, pages e71670.
Crossref
Crossref
Roland Hubaux, Kelsie L. Thu, Bradley P. Coe, Calum MacAulay, Stephen Lam & Wan L. Lam. (2013) EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation. Journal of Thoracic Oncology 8:8, pages 1102-1106.
Crossref
Crossref
Shelly Seward, Assaad Semaan, Aamer M. Qazi, Oksana V. Gruzdyn, Sreedhar Chamala, Christopher C. Bryant, Sanjeev Kumar, David Cameron, Seema Sethi, Rouba Ali-Fehmi, Robert Morris, David L. Bouwman, Adnan R. Munkarah, Donald W. Weaver, Scott A. Gruber & Ramesh B. Batchu. (2013) EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53. Cancer Letters 336:1, pages 53-60.
Crossref
Crossref
Yi Zhang, Guangpu Liu, Changwei Lin, Guoqing Liao & Bo Tang. (2013) Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sciences 92:17-19, pages 896-902.
Crossref
Crossref
YAN KUANG, JING CAI, DONGLIN LI, QIN HAN, JIN CAO & ZEHUA WANG. (2013) Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncology Letters 5:4, pages 1149-1154.
Crossref
Crossref
Junjie Wang, Lili Yu, Jing Cai, Jinghui Jia, Yanping Gao, Minglin Liang & Zehua Wang. (2013) The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial ovarian cancer. Biochemical and Biophysical Research Communications 433:4, pages 470-476.
Crossref
Crossref
BO TANG, YI ZHANG, RUI LIANG, ZHENMING GAO, DEGUANG SUN & LIMING WANG. (2013) RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncology Reports 29:3, pages 1037-1042.
Crossref
Crossref
Irina Alimova, Diane K. Birks, Peter S. Harris, Jeffrey A. Knipstein, Sujatha Venkataraman, Victor E. Marquez, Nicholas K. Foreman,Rajeev Vibhakar. (2013) Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro-Oncology 15:2, pages 149-160.
Crossref
Crossref
Wei Yu, Chengmeng Jin, Xiaoyan Lou, Xu Han, Lisha Li, Yinghua He, Hongyu Zhang, Kelong Ma, Jingde Zhu, Lihua Cheng & Biaoyang Lin. (2011) Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell. PLoS ONE 6:12, pages e29450.
Crossref
Crossref
C Nishioka, T Ikezoe, J Yang, K Udaka & A Yokoyama. (2011) Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins. Blood Cancer Journal 1:12, pages e48-e48.
Crossref
Crossref
Marie E. Maradeo & Paul Cairns. (2011) Translational application of epigenetic alterations: Ovarian cancer as a model. FEBS Letters 585:13, pages 2112-2120.
Crossref
Crossref
Monica Mann, Valerie Cortez & Ratna K. Vadlamudi. (2011) Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy. Cancers 3:2, pages 1691-1707.
Crossref
Crossref
Kenneth J. O’Byrne, Martin P. Barr & Steven G. Gray. (2011) The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers 3:1, pages 1426-1453.
Crossref
Crossref
Jianfeng Guo, Jing Cai, Lili Yu, Huijuan Tang, Chunyan Chen & Zehua Wang. (2011) EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Science 102:3, pages 530-539.
Crossref
Crossref
Siân Rizzo, Jenny M. Hersey, Paul Mellor, Wei Dai, Alessandra Santos-Silva, Daniel Liber, Louisa Luk, Ian Titley, Craig P Carden, Garry Box, David L. Hudson, Stanley B. Kaye & Robert Brown. (2011)
Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress
EZH2
. Molecular Cancer Therapeutics 10:2, pages 325-335.
Crossref
Crossref